Research Papers: Therapeutic

CT26 murine colon carcinoma expressing the red fluorescent protein KillerRed as a highly immunogenic tumor model

[+] Author Affiliations
Diana V. Yuzhakova

Institute of Biomedical Technologies, Nizhny Novgorod State Medical Academy, Minin and Pozharsky Square, 10/1, Nizhny Novgorod 603005, Russia

Lobachevsky State University of Nizhny Novgorod, Gagarina Avenue, 23, Nizhny Novgorod 603950, Russia

Marina V. Shirmanova, Irina N. Druzhkova, Boris E. Shakhov, Elena V. Zagaynova

Institute of Biomedical Technologies, Nizhny Novgorod State Medical Academy, Minin and Pozharsky Square, 10/1, Nizhny Novgorod 603005, Russia

Ekaterina O. Serebrovskaya

Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS, Miklukho-Maklaya Street, 16/10, Moscow 117997, Russia

Konstantin A. Lukyanov

Institute of Biomedical Technologies, Nizhny Novgorod State Medical Academy, Minin and Pozharsky Square, 10/1, Nizhny Novgorod 603005, Russia

Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS, Miklukho-Maklaya Street, 16/10, Moscow 117997, Russia

Sergey A. Lukyanov

Institute of Biomedical Technologies, Nizhny Novgorod State Medical Academy, Minin and Pozharsky Square, 10/1, Nizhny Novgorod 603005, Russia

Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS, Miklukho-Maklaya Street, 16/10, Moscow 117997, Russia

Pirogov Russian National Research Medical University, Ostrovitianova Street, 1, Moscow 117997, Russia

J. Biomed. Opt. 20(8), 088002 (Aug 17, 2015). doi:10.1117/1.JBO.20.8.088002
History: Received March 2, 2015; Accepted July 20, 2015
Text Size: A A A

Abstract.  The development of tumor therapies based on the activation of antitumor immunity requires tumor models that are highly immunogenic. The immunologic response to fluorescent proteins, green fluorescent protein (GFP), or enhanced GFP (EGFP) was demonstrated in different cancer models. However, for live animal imaging, red and far-red fluorescent proteins are preferable, but their immunogenicity has not been studied. We assessed the immunogenicity of the red fluorescent protein, KillerRed (KR), in CT26 murine colon carcinoma. We showed a slower growth and a lower tumor incidence of KR-expressing tumors in comparison with nonexpressing ones. We found that KR-expressing lung metastases and rechallenged tumors were not formed in mice that had been surgically cured of KR-expressing primary tumors. The effect of low-dose cyclophosphamide (CY) treatment was also tested, as this is known to activate antitumor immune responses. The low-dose CY therapy of CT26-KR tumors resulted in inhibition of tumor growth and improved mouse survival. In summary, we have established a highly immunogenic tumor model that could be valuable for investigations of the mechanisms of antitumor immunity and the development of new therapeutic approaches.

Figures in this Article
© 2015 Society of Photo-Optical Instrumentation Engineers

Citation

Diana V. Yuzhakova ; Marina V. Shirmanova ; Ekaterina O. Serebrovskaya ; Konstantin A. Lukyanov ; Irina N. Druzhkova, et al.
"CT26 murine colon carcinoma expressing the red fluorescent protein KillerRed as a highly immunogenic tumor model", J. Biomed. Opt. 20(8), 088002 (Aug 17, 2015). ; http://dx.doi.org/10.1117/1.JBO.20.8.088002


Access This Article
Sign in or Create a personal account to Buy this article ($20 for members, $25 for non-members).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Related Book Chapters

Topic Collections

PubMed Articles
Advertisement
  • Don't have an account?
  • Subscribe to the SPIE Digital Library
  • Create a FREE account to sign up for Digital Library content alerts and gain access to institutional subscriptions remotely.
Access This Article
Sign in or Create a personal account to Buy this article ($20 for members, $25 for non-members).
Access This Proceeding
Sign in or Create a personal account to Buy this article ($15 for members, $18 for non-members).
Access This Chapter

Access to SPIE eBooks is limited to subscribing institutions and is not available as part of a personal subscription. Print or electronic versions of individual SPIE books may be purchased via SPIE.org.